Navigate BioPharma
Private Company
Funding information not available
Overview
Navigate BioPharma is a privately held, revenue-generating contract research organization (CRO) providing critical biomarker and diagnostic testing services for clinical trials. The company leverages a multi-platform, technology-agnostic approach to deliver validated assays, with deep expertise in complex therapeutic areas like cell & gene therapy and oncology. With over 15 years of experience and a strong regulatory track record with agencies like the FDA and EMA, Navigate positions itself as a strategic partner to mitigate risks and accelerate the drug development and approval process for its biopharmaceutical clients.
Technology Platform
Technology-agnostic suite of biomarker assay platforms including genomics (NGS, PCR), flow cytometry, ligand binding assays (ELISA, MSD), and digital pathology. Capabilities span DNA, RNA, protein, cell, and tissue-based analysis for clinical trial support.
Opportunities
Risk Factors
Competitive Landscape
Competes with large, full-service CRO central labs (e.g., LabCorp, IQVIA, PPD), specialized clinical biomarker labs (e.g., Q2 Solutions, NeoGenomics), and diagnostic companies offering companion diagnostic co-development. Differentiation is based on deep therapeutic expertise, a multi-platform approach, and a specific focus on complex modalities like cell & gene therapy.